Navtemadlin — Investigational Agent
Other · Phase 3 · Kartos Therapeutics
Mechanism of Action
Oral selective MDM2 inhibitor that disrupts MDM2-p53 binding to restore p53 activity, promoting apoptosis of malignant clones; investigated in TP53-wildtype myelofibrosis, often added to ruxolitinib.
Investigational Indications
- Myelofibrosis
- Polycythemia vera